Drug delivery in the Twenty-First Century: A New Paradigm

Clinical Pharmacology and Therapeutics

Volumn 85, Issue 5, 2009, Pages 451-455

  Smith, B ^a   Uhl, K ^b  

^a AMGEN INC   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INJECTABLE CONTRACEPTIVE AGENT; NICOTINE; ORAL CONTRACEPTIVE AGENT; PLACEBO; RIVASTIGMINE;

ALZHEIMER DISEASE; BARE METAL STENT; CIGARETTE SMOKING; CONTRACEPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG ELUTING STENT; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; HUMAN; NANOTECHNOLOGY; NAUSEA; PATIENT COMPLIANCE; PRIORITY JOURNAL; REGENERATIVE MEDICINE; STENT THROMBOSIS; TOBACCO; TRANSDERMAL PATCH;

DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; NANOTECHNOLOGY; NICOTINE; PHARMACEUTICAL PREPARATIONS; STEM CELLS; TOBACCO;

EID: 65249128587     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.31     Document Type: Editorial

References (16)

1. Lefèvre, G. et al. Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients. Clin. Pharmacol. Ther. 83, 106-114 (2008).
2. Winblad, B. et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease - rivastigmine patch versus capsule. Int. J. Geriatr. Psychiatry 22, 456-467 (2007).
3. Gately, I. La Diva Nicotina: The Story of How Tobacco Seduced the World (Simon & Schuster, New York, 2001).
4. Wilbert, J. Tobacco and Shamanism in South America (Yale University Press, New Haven, CT, 1987).
5. Benowitz, N.L. Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction. Clin. Pharmacol. Ther. 83, 531-541 (2008).
6. Reuters press release. High Growth Reported for the US Drug Delivery Systems Market (11 March 2008).
7. Lauritsen, K.J. Combination products regulation at the FDA. Clin. Pharmacol. Ther. 85, 468-470 (2009).
8. Maluenda, G., Lemesle, G. & Waksman, R. A critical appraisal of the safety and efficacy of drug-eluting stents. Clin. Pharmacol. Ther. 85, 474-480 (2009).
9. Bartunek, J., Sherman, W., Vanderheyden, M., Fernandez-Aviles, F., Wijns, W. & Terzic, A. Delivery of biologics in cardiovascular regenerative medicine. Clin. Pharmacol. Ther. 85, 548-552 (2009).
10. Novack, G.D. Ophthalmic drug delivery: development and regulatory considerations. Clin. Pharmacol. Ther. 85, 539-543 (2009).
11. Merkatz, R.B., Tokay, B. & Sitruk-Ware, R.L. Methods for female contraception: a model for innovation in drug delivery systems. Clin. Pharmacol. Ther. 85, 553-557 (2009).
12. Zhang, L., Gu, F.X., Chan, J.M., Wang, A.Z., Langer, R.S. & Farokhzad, O.C. Nanoparticles in medicine: therapeutic applications and developments. Clin. Pharmacol. Ther. 83, 761-769 (2007).
13. Lawson, L.B., Freytag, L.C., Clements, J.D. & Clements, J.D. Use of nanocarriers for transdermal vaccine delivery. Clin. Pharmacol. Ther. 82, 641-643 (2007).
14. Elman, N.M., Patta, Y., Scott, A.W., Masi, B., Ho Duc, H.L. & Cima, M.J. The next generation of drug-delivery microdevices. Clin. Pharmacol. Ther. 85, 544-547 (2009).
15. Orringer, D.A., Koo, Y.E., Chen, T., Kopelman, R., Sagher, O. & Philbert, M.A. Small solutions for big problems: the application of nanoparticles to brain tumor diagnosis and therapy. Clin. Pharmacol. Ther. 85, 531-534 (2009).
16. Ferrari, M., Philibert, M.A. & Sanhai, W.R. Nanomedicine and society. Clin. Pharmacol. Ther. 85, 466-467 (2009).